Transaction · 0001193125-26-447899

Vieira Roberto Wandenkolk

Vieira Roberto Wandenkolk, PRES, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 6657.000000 shares for an estimated $537436.92. Reported holdings after the transaction were 5622.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES
CORTCORCEPT THERAPEUTICS INC
Trade date
Nov 02, 2026
Filing date
Nov 05, 2026
View on SEC Insider profile
Disclosed value-$537kShares × reported price
Shares traded6.65k$80.73 per share
Holdings after5.62kDirect
% of reported position traded54.21%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 12,279 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CORT price since this filing

Daily closing prices, with the filing date and available return windows
CORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +46.7%1w ago +10.0%1d ago +2.4%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-447899
Common Stock
Transaction date
Nov 02, 2026
Filed Nov 05, 2026, 12:20 AM · 3d delay
Shares
6,657 sh
$80.73 per share
Estimated value
-$537k
Computed from shares × price
Holdings after
5,622 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Reduction Large Sale 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, Oncology

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…

  2. F2

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the…

  3. F3

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sa…

  4. F4

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sa…

  5. F5

    Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable…

Original filing · 0001193125-26-447899
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CORT